TEDA Establishes a Whole Industry Chain One-Stop Service Platform for Nucleic Acid Medicines
Recently, at the Summit on Small Nucleic Acid Industry Development, the Tianjin Whole Industry Chain One-Stop Service Platform for Nucleic Acid Medicines was officially established. This platform is jointly built by the Tianjin (TEDA) Nucleic Acid Industry Alliance and the Asymchem Inc., along with other relevant enterprises and institutions in the nucleic acid industry of TEDA. It will leverage the resources of the Nucleic Acid Industry Alliance and the advantages of the nucleic acid medicines industry cluster in TEDA to primarily provide services for nucleic acid medicine research, development, analysis, verification, and commercialization. The services offered will cover the whole process, including chemical manufacturing and control (CMC), pre-clinical research, clinical development strategies, clinical trial design, and registration applications.
In the future, the platform will continuously explore a business cooperation pattern of “resources + capital + services”. Simultaneously, it will integrate technological innovation and R&D efforts, strengthening the interconnectivity and collaboration along the whole nucleic acid medicine industry chain. The platform’s ultimate goal is to become a highly influential and competitive industry service platform, not only in China but also worldwide.